Tofacitinib en el tratamiento de la colitis ulcerosa: casos clínicos / Tofacitinib for the treatment of ulcerative colitis: report of two cases
Rev. méd. Chile
;
148(7): 1039-1043, jul. 2020. graf
Article
in Spanish
| LILACS
| ID: biblio-1139408
RESUMEN
Biological therapy dramatically changed the management of Ulcerative Colitis (UC). However, a significant number of these patients fail to respond or have secondary loss of response to this strategy. In this clinical situation, the options include intensification of anti-TNF therapy, the use of a second anti-TNF or being switched to another drug class. Among the later, tofacitinib, an oral small molecule directed against the JAK/STAT pathway, is safe and effective in inducing and maintaining remission in patients with moderate-severe UC. We report two patients with UC refractory to conventional treatment and biological therapy, who responded successfully to the use of tofacitinib.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Piperidines
/
Pyrimidines
/
Colitis, Ulcerative
/
Protein Kinase Inhibitors
Limits:
Humans
/
Male
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2020
Type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Clínica Las Condes/CL
/
Facultad de Medicina Universidad/CL
Similar
MEDLINE
...
LILACS
LIS